A Non Interventional Study With Oxaliplatin Onkovis (Oxaliplatin) Utilized for the Treatment of Cancer

Onkovis

Status: Completed

Conditions: Carcinoma

Study type: Observational

Funder types: Industry

Identifiers

NCT01942200

ONKOOXA01

Details and patient eligibility

About

The main purpose of this observational study with Oxaliplatin onkovis is to determine the number of treatment cycles and the quantity of Oxaliplatin onkovis needed for this purpose under the special circumstances of ambulant chemotherapy.

Onkovis aims to contribute to an economical utilization of the chemotherapeutics. This includes provision of appropriate packaging sizes to decrease the excess quantity to be discarded, and thus also follows this objective.

Secondary objective is the assessment of the side effects of Oxaliplatin onkovis. To this end, data regarding co-medication and adverse events are also collected.

Enrollment: 383 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Indication for Oxaliplatin according to the Summary of Product Characteristics (SmPC) and treating physician

Exclusion criteria

• According to the Oxaliplatin SmPC

Trial design

383 participants in 1 patient group

Carcinoma, Oxaliplatin onkovis (Oxaliplatin)

Description:

Treatment in combination therapy for adjuvant treatment of colon carcinoma of stage III (Dukes C) after complete removal of the primary tumor, as well as for treatment of metastasizing colorectal carcinoma.